VeraDermics (MANE) news
Recent news
Veradermics Inc: Citigroup raises target price to $160 from $135
Citigroup has raised its price target for Veradermics, Incorporated (NYSE: MANE) to $160 from $135, maintaining a positive outlook on the stock. This adjustment follows the company’s announcement of positive topline results from Part A of its Phase 2/3 trial for VDPHL01, an extended-release oral…
AInvest Wire · Jul 16, 2026ImportantVeradermics shares gain nearly 14% after oral hair loss drug shows positive mid-stage data in women
AInvest Wire · Jul 15, 2026Veradermics - expects Phase 2/3 study '306' top-line results in 1H 2027
AInvest Wire · Jul 15, 2026Veradermics Inc: B. Riley initiates coverage with buy rating; target price $170
Veradermics, Incorporated (NYSE: MANE) has recently attracted attention from analysts following B. Riley’s initiation of coverage with a "Buy" rating and a target price of $170. This move aligns with a broader trend of growing investor interest in the company, driven by recent clinical progress and…
AInvest Wire · Jul 15, 2026NYSE order imbalance MANE.N 29805.0 shares on sell side
On June 17, 2026, the NYSE reported a significant order imbalance for Veradermics, Inc. (MANE.N), with 29,805 shares concentrated on the sell side during an auction session. This imbalance reflects a temporary disparity between buy and sell orders, which can influence liquidity and price dynamics…
AInvest Wire · Jun 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.